noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Regeneron Pharmaceuticals Inc.

Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements[...]
Honeywell International Incorporation

Honeywell Portfolio Update Presentation
Faraday Future Intelligent[...]

Faraday Future Announces Acceptance of 10% Share Donation of Global IP[...]

Healthcare

Regeneron Pharmaceuticals Inc.

10/09/2024 | Press release | Distributed by Public on 10/08/2024 22:52

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

Sharing and Personal Tools

Please select the service you want to use:

Smartlinks | Regeneron Pharmaceuticals Inc. | News | Health | Science | Research | Company News | Business Announcement | Products and Services | Securities Issuers | Biotechnology and Medical Research Companies | Borsa Italiana | London Stock Exchange (LSE) | Frankfurt Stock Exchange | Sao Paulo Stock Exchange (B3) | Vienna Stock Exchange (ATX) | Berlin Stock Exchange | Dusseldorf Stock Exchange | Hamburg Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Bolsa Mexicana de Valores (BMV) | Lima Stock Exchange (BVL) | Moscow Exchange (MOEX) | BX Swiss | Tradegate Exchange | XETRA | NYSE American | NYSE ARCA Equities | Nasdaq Global Select Market | Cboe BZX Exchange | Cboe Off Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | FINRA Alternative Display Facility (ADF) | EuroTLX | Bolsa Institucional de Valores (BIVA) | Hannover Stock Exchange | Nasdaq BX | Nasdaq PSX | NYSE Chicago | Turquoise

Back

Download the original document